Agency
County of Robeson Office of Treasurer
County of Robeson Office of Treasurer was paid $6.06M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99199, Unlisted special service, procedure or report — 55% of everything it billed.
33Billing provider infoCOUNTY OF ROBESON OFFICE OF TREASURER
LUMBERTON, NC 28360
LUMBERTON, NC 28360
33aNPI1932287182assigned 11/02/2006
33bProvider typeCase Management Agency
28Total paid$6.06M
24GClaims788,556
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Management Agency providers in North Carolina
Rank by total paid#49 of 195
Median peer was paid$2.05M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,378 | $356K | |
| 2019 | 16,659 | $308K | |
| 2020 | 13,962 | $324K | |
| 2021 | 106,122 | $1.04M | |
| 2022 | 213,683 | $1.40M | |
| 2023 | 200,467 | $1.21M | |
| 2024incomplete | 217,285 | $1.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99199 | Unlisted special service, procedure or report | 55% | 658,120 | 592,109 | $3.33M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 12,693 | 9,902 | $920K |
| 0001A | 2.6% | 2,964 | 2,518 | $159K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.5% | 1,384 | 1,007 | $151K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.1% | 1,545 | 1,233 | $130K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.0% | 1,490 | 1,252 | $121K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2.0% | 4,561 | 3,790 | $119K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.9% | 8,713 | 7,145 | $114K |
| 0002A | 1.4% | 1,858 | 1,565 | $86K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.4% | 535 | 470 | $83K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.1% | 720 | 608 | $64K |
| 99502 | 1.0% | 983 | 954 | $63K |
102 more codes
| T1002 | Rn services, up to 15 minutes | <1% | 2,079 | $59K |
| 99501 | <1% | 1,086 | $56K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 462 | $55K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,024 | $55K |
| S0280 | Medical home program, comprehensive care coordination and planning, initial plan | <1% | 861 | $44K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 345 | $39K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 451 | $37K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,127 | $32K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,360 | $31K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,010 | $25K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,736 | $24K |
| 76801 | <1% | 185 | $22K | |
| 87210 | <1% | 5,400 | $21K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 644 | $20K |
| 0071A | <1% | 285 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,980 | $15K |
| 0004A | <1% | 269 | $15K | |
| 81025 | <1% | 1,833 | $13K | |
| 0072A | <1% | 204 | $12K | |
| 85013 | <1% | 4,029 | $10K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 80 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 750 | $10K |
| 0012A | <1% | 161 | $9K | |
| D1206 | Topical application of fluoride varnish | <1% | 643 | $9K |
| 81003 | <1% | 2,519 | $6K | |
| 81001 | <1% | 1,822 | $6K | |
| 0064A | <1% | 115 | $6K | |
| 0011A | <1% | 182 | $5K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 33 | $5K |
| 90734 | <1% | 1,486 | $4K | |
| 82120 | <1% | 1,137 | $4K | |
| 90651 | <1% | 827 | $4K | |
| 96160 | <1% | 1,234 | $4K | |
| 83986 | <1% | 1,141 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,239 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,254 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 489 | $3K |
| 92551 | <1% | 1,604 | $3K | |
| 90474 | <1% | 215 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 45 | $3K |
| 90686 | <1% | 2,415 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,914 | $2K |
| 96161 | <1% | 508 | $2K | |
| 99173 | <1% | 2,613 | $1K | |
| 87807 | <1% | 67 | $892.76 | |
| 90715 | <1% | 910 | $776.93 | |
| 0124A | <1% | 26 | $755.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 314 | $565.42 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 689 | $440.40 |
| 82947 | <1% | 101 | $398.67 | |
| 87076 | <1% | 75 | $390.26 | |
| 96127 | <1% | 89 | $304.72 | |
| 83655 | <1% | 173 | $211.07 | |
| 82950 | <1% | 31 | $161.79 | |
| 90619 | <1% | 321 | $160.02 | |
| 86592 | <1% | 1,665 | $139.08 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 310 | $129.19 |
| 80061 | Lipid panel | <1% | 228 | $125.25 |
| 86803 | <1% | 111 | $59.63 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 524 | $55.69 |
| 86593 | <1% | 710 | $33.00 | |
| 94760 | <1% | 320 | $6.26 | |
| 36416 | <1% | 1,182 | $3.76 | |
| 86900 | <1% | 360 | $3.00 | |
| 91300 | <1% | 5,302 | $0.02 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 28 | $0.02 |
| 99000 | 0% | 4,419 | $0.00 | |
| 91307 | 0% | 580 | $0.00 | |
| 90723 | 0% | 1,232 | $0.00 | |
| 86762 | 0% | 346 | $0.00 | |
| 90647 | 0% | 1,105 | $0.00 | |
| 92558 | 0% | 927 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 122 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 93 | $0.00 |
| 87340 | 0% | 343 | $0.00 | |
| 80053 | Comprehensive metabolic panel | 0% | 151 | $0.00 |
| 90656 | 0% | 108 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 64 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 194 | $0.00 |
| 91301 | 0% | 340 | $0.00 | |
| 90677 | 0% | 106 | $0.00 | |
| 91306 | 0% | 107 | $0.00 | |
| 90680 | 0% | 16 | $0.00 | |
| 0500F | 0% | 27 | $0.00 | |
| 90696 | 0% | 16 | $0.00 | |
| 90670 | 0% | 1,492 | $0.00 | |
| G0452 | Molecular pathology procedure; physician interpretation and report | 0% | 15 | $0.00 |
| 90633 | 0% | 844 | $0.00 | |
| 90681 | 0% | 173 | $0.00 | |
| 83020 | 0% | 358 | $0.00 | |
| 90710 | 0% | 235 | $0.00 | |
| 86787 | 0% | 321 | $0.00 | |
| 99177 | 0% | 357 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 135 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 58 | $0.00 |
| 84439 | 0% | 76 | $0.00 | |
| 90672 | 0% | 88 | $0.00 | |
| 90707 | 0% | 12 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 116 | $0.00 |
| 90700 | 0% | 18 | $0.00 | |
| 91312 | 0% | 25 | $0.00 | |
| 90685 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACKSON, SUZANNE (HEALTH DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| County of Robeson Office of Treasurer | Lumberton, NC | $1.09M |
| County of Robeson Office of Treasurer | Lumberton, NC | $91.84 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.